Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System.
Torres A, Soriano A, Rivolo S, Remak E, Peral C, Kantecki M, Ansari W, Charbonneau C, Hammond J, Grau S, Wilcox M. Torres A, et al. Among authors: kantecki m. Clinicoecon Outcomes Res. 2022 Mar 18;14:149-161. doi: 10.2147/CEOR.S329494. eCollection 2022. Clinicoecon Outcomes Res. 2022. PMID: 35330907 Free PMC article.
Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam.
Sánchez-García M, Hammond J, Yan JL, Kantecki M, Ansari W, Dryden M. Sánchez-García M, et al. Among authors: kantecki m. Infect Dis Ther. 2020 Sep;9(3):609-623. doi: 10.1007/s40121-020-00297-3. Epub 2020 Jun 30. Infect Dis Ther. 2020. PMID: 32607967 Free PMC article.
Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials.
Wilcox M, Yan JL, Gonzalez PL, Dryden M, Stone GG, Kantecki M. Wilcox M, et al. Among authors: kantecki m. Infect Dis Ther. 2022 Feb;11(1):217-230. doi: 10.1007/s40121-021-00557-w. Epub 2021 Nov 6. Infect Dis Ther. 2022. PMID: 34741280 Free PMC article.
Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Barnes R, et al. Among authors: kantecki m. Clin Ther. 2015 Jun 1;37(6):1317-1328.e2. doi: 10.1016/j.clinthera.2015.03.021. Epub 2015 Apr 17. Clin Ther. 2015. PMID: 25891805 Free article.
Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.
Drgona L, Khachatryan A, Stephens J, Charbonneau C, Kantecki M, Haider S, Barnes R. Drgona L, et al. Among authors: kantecki m. Eur J Clin Microbiol Infect Dis. 2014 Jan;33(1):7-21. doi: 10.1007/s10096-013-1944-3. Epub 2013 Sep 12. Eur J Clin Microbiol Infect Dis. 2014. PMID: 24026863 Free PMC article. Review.
24 results